Dr Danilov on Therapeutic Options After BTK Inhibitors in MCL onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Published: Jun 09, 2021
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE)
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16
th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below.
Poster Presentation Title
: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies
Abstract Book Number: 236
Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia